Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MEI Pharma's share price for the quarter that ended in Sep. 2024 was $2.85. MEI Pharma's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 6.66 Mil. Therefore, MEI Pharma's market cap for the quarter that ended in Sep. 2024 was $18.99 Mil.
MEI Pharma's quarterly market cap
declined
from Mar. 2024 ($26.65 Mil) to Jun. 2024 ($19.39 Mil) and
declined
from Jun. 2024 ($19.39 Mil) to Sep. 2024 ($18.99 Mil).
MEI Pharma's annual market cap
declined
from Jun. 2022 ($80.56 Mil) to Jun. 2023 ($43.84 Mil) and
declined
from Jun. 2023 ($43.84 Mil) to Jun. 2024 ($19.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MEI Pharma's Enterprise Value for Today is $-19.69 Mil.
MEI Pharma Market Cap Historical Data
The historical data trend for MEI Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MEI Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Market Cap falls into.
MEI Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MEI Pharma's Market Cap for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma (NAS:MEIP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MEI Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 